HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

AbstractPURPOSE:
To report the impact of radiotherapy quality on outcome in a large international phase III trial evaluating radiotherapy with concurrent cisplatin plus tirapazamine for advanced head and neck cancer.
PATIENTS AND METHODS:
The protocol required interventional review of radiotherapy plans by the Quality Assurance Review Center (QARC). All plans and radiotherapy documentation underwent post-treatment review by the Trial Management Committee (TMC) for protocol compliance. Secondary review of noncompliant plans for predicted impact on tumor control was performed. Factors associated with poor protocol compliance were studied, and outcome data were analyzed in relation to protocol compliance and radiotherapy quality.
RESULTS:
At TMC review, 25.4% of the patients had noncompliant plans but none in which QARC-recommended changes had been made. At secondary review, 47% of noncompliant plans (12% overall) had deficiencies with a predicted major adverse impact on tumor control. Major deficiencies were unrelated to tumor subsite or to T or N stage (if N+), but were highly correlated with number of patients enrolled at the treatment center (< five patients, 29.8%; > or = 20 patients, 5.4%; P < .001). In patients who received at least 60 Gy, those with major deficiencies in their treatment plans (n = 87) had a markedly inferior outcome compared with those whose treatment was initially protocol compliant (n = 502): -2 years overall survival, 50% v 70%; hazard ratio (HR), 1.99; P < .001; and 2 years freedom from locoregional failure, 54% v 78%; HR, 2.37; P < .001, respectively.
CONCLUSION:
These results demonstrate the critical importance of radiotherapy quality on outcome of chemoradiotherapy in head and neck cancer. Centers treating only a few patients are the major source of quality problems.
AuthorsLester J Peters, Brian O'Sullivan, Jordi Giralt, Thomas J Fitzgerald, Andy Trotti, Jacques Bernier, Jean Bourhis, Kally Yuen, Richard Fisher, Danny Rischin
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 28 Issue 18 Pg. 2996-3001 (Jun 20 2010) ISSN: 1527-7755 [Electronic] United States
PMID20479390 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Triazines
  • Tirapazamine
  • Cisplatin
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, pathology, radiotherapy)
  • Cisplatin (administration & dosage)
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Follow-Up Studies
  • Guideline Adherence
  • Head and Neck Neoplasms (drug therapy, pathology, radiotherapy)
  • Humans
  • International Agencies
  • Neoplasm Recurrence, Local (drug therapy, pathology, radiotherapy)
  • Neoplasm Staging
  • Quality Assurance, Health Care
  • Radiotherapy Dosage
  • Survival Rate
  • Tirapazamine
  • Treatment Outcome
  • Triazines (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: